The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment

2015 ◽  
pp. 627-633 ◽  
Author(s):  
Robert J. Gil ◽  
Jacek Bil ◽  
Tomasz Pawłowski ◽  
Nabijon Yuldashev ◽  
Leszek Kołakowski ◽  
...  
Keyword(s):  
Stable Coronary Artery Disease ◽  
Special Focus ◽  
Bioresorbable Vascular Scaffold ◽  
Vascular Scaffold ◽  
Vascular Scaffolds ◽  
Drug Eluting ◽  
Bioresorbable Vascular Scaffolds ◽  
Artery Disease ◽  
Absorb Bvs ◽  
One Year

scholarly journals How to Select the Most Appropriate Patient and Lesion to be Treated with a Coronary Bioresorbable Vascular Scaffold

2013 ◽  
Vol 8 (2) ◽  
pp. 90
Author(s):  
Charis Costopoulos ◽  
Azeem Latib ◽  
Antonio Colombo ◽  
◽  
◽  
...  
Keyword(s):  
Percutaneous Treatment ◽  
Bioresorbable Vascular Scaffold ◽  
Diffuse Disease ◽  
Novel Treatment ◽  
Vascular Scaffold ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds ◽  
Artery Disease ◽  
Novel Devices ◽  
Complex Lesions

Bioresorbable vascular scaffolds (BVS) are an exciting novel treatment for coronary artery disease (CAD) as their eventual resorption renders the artery free from a permanent metallic cage. Clinical trials regarding these novel devices have demonstrated promising results, although their use in this context has largely been restricted to simple lesions. More recently, BVS use has expanded to patients with more complex lesions including those with long diffuse disease, and results from several registries are awaited with regard to their efficacy in ‘real-world’ patients. Although any patient who requires percutaneous treatment for CAD could benefit from BVS implantation, there are certain cohorts of patients and lesions in whom BVS could be of particular benefit. In this review, we attempt to identify which patient and lesion cohort is most suitable for treatment with these novel devices.

scholarly journals Pre-Emptive OCT-Guided Angioplasty of Vulnerable Intermediate Coronary Lesions: Results from the Prematurely Halted PECTUS-Trial

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jan-Quinten Mol ◽  
Michiel J. Bom ◽  
Peter Damman ◽  
Paul Knaapen ◽  
Niels van Royen
Keyword(s):  
Composite Endpoint ◽  
Coronary Intervention ◽  
Future Research ◽  
Fractional Flow ◽  
Bioresorbable Vascular Scaffold ◽  
Flow Reserve ◽  
Vulnerable Plaques ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds ◽  
Absorb Bvs

Objectives. To assess the safety and efficacy of pre-emptive treatment of optical coherence tomography- (OCT-) derived vulnerable, non-flow-limiting, non-culprit lesions in patients with myocardial infarction (MI). Background. Intracoronary imaging with OCT can aid in the decision to treat non-flow-limiting lesions by identifying vulnerable plaques. Pre-emptive treatment of these lesions might improve patient outcome by “sealing” these plaques. Bioresorbable vascular scaffolds (BVS) have theoretical benefit for this treatment because they dissolve completely over time. Methods. In patients presenting with MI, non-culprit lesions with a fractional flow reserve ≥0.8 were imaged with OCT. Vulnerable plaques were randomised to either percutaneous coronary intervention (PCI) with bioresorbable vascular scaffold (BVS) placement or optimal medicinal therapy (OMT). The primary outcome was a composite of all-cause mortality, non-fatal MI, and unplanned revascularisation at 1-year follow-up. Results. The trial was stopped prematurely after retraction from the market of the Absorb BVS. At that time, a total of 34 patients were randomised. At two years, the composite endpoint occurred 3 times (18.8%) in the BVS group and 1 time (6.3%) in the OMT group. Apart from one elective PCI for stable angina in the OMT group, no target lesions in any group were revascularised. Conclusions. Pre-emptive stenting of vulnerable plaques had no evident benefit compared to conservative treatment. However, due to the low number of included patients, no definite conclusions could be drawn. Identifying and potentially treating vulnerable plaques remains an important target for future research. This trial is registered under https://www.trialregister.nl/trial/NL4177 on 08-12-2015.

scholarly journals Everolimus-eluting bioresorbablecoronary scaffold in Asian patients; a 2-yearfollow-up

2020 ◽  
pp. 1-11
Author(s):  
Muhammad Abdul Salam Azad ◽  
Uzma Gul ◽  
Asim Javed
Keyword(s):  
Case Series ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Asian Patients ◽  
Implantation Techniques ◽  
Bioresorbable Stent ◽  
Vascular Scaffolds ◽  
Drug Eluting ◽  
Artery Disease ◽  
Absorb Bvs

Abstract Indo-Pakistan population has one of the highest risk of coronary artery disease(CAD) in the world.1Percutaneous interventions with the use of stents has been the mainstay of treatment for CAD, evolving from balloon angioplasty to bare metal stents and then to drug eluting stents. However, there are a few drawbacks related to the metal implant in the coronary, leading to the development of bio-resorbable vascular scaffolds(BVS). This case series studies the implantation techniques and 24 month clinical outcome of bioresorbable stent Absorb at Rawalpindi Institute of Cardiology. From November 1, 2013 till June 30, 2018. Fifty patients undergoing angioplasty with Absorb BVS as elective or primary PCI were enrolled. Case selection was at the discretion of the operator. Patients were followed up clinically. Repeat angiogram was conducted if clinically indicated.  Continuous...  

Sign in / Sign up

Export Citation Format

Share Document